The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B; wherein the ring Q is a benzene ring; J.sup.2-J.sup.1 is N.dbd.CR.sup.7 or R.sup.1aN--CO; G is OH or NR.sup.5R.sup.6; E is CONR.sup.7, NR.sup.7CO, C(R.sup.8).dbd.C(R.sup.8) or (X).sub.m(CR.sup.8R.sup.8a).sub.n where X is O, S or NR.sup.7; provided that when J.sup.2-J.sup.1 is R.sup.1aN--CO, E is other than NR.sup.7CO; m and n are each 0 or 1, where m+n=1 or 2; A is a bond and R.sup.4 and R.sup.4a are absent or A is a saturated optionally substituted C.sub.1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R.sup.1, R.sup.1a, R.sup.2, and R.sup.3 are each H; halogen; C.sub.1-6 hydrocarbyl optionally substituted by halogen, OH or C.sub.1-2 alkoxy; CN; CONHR.sup.8; NH.sub.2; NHCOR.sup.10 or NHCONHR.sup.10; R.sup.4 is H or C.sub.1-4 alkyl; R.sup.4a is H, C.sub.1-4 alkyl or a group R.sup.9; R.sup.5 and R.sup.6 are each selected from H, R.sup.9 and C.sub.1-4 hydrocarbyl optionally substituted by halogen, C.sub.1-2 alkoxy or R.sup.9; or NR.sup.5R.sup.6 forms a saturated 4-7 membered monocyclic heterocyclic group; R.sup.7 is H or C.sub.1-4 alkyl; R.sup.8 and R.sup.8a each H or saturated C.sub.1-4 hydrocarbyl optionally substituted by fluorine; R.sup.9 is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R.sup.4, R.sup.4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR.sup.5R.sup.6, R.sup.4 and A form a saturated 4-7 membered monocyclic heterocycle; or R.sup.4, together with R.sup.7 or R.sup.8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR.sup.5R.sup.6 and R.sup.7 or R.sup.8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R.sup.10 is optionally substituted phenyl or benzyl.

 
Web www.patentalert.com

< Dpp-Iv Inhibitors

> Pharmaceutical Composition

~ 00475